| Biotechnology Industry | Healthcare Sector | - CEO | XETRA Exchange | DE000A40ZVN7 ISIN |
| Germany Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Viromed Medical AG, formerly known as Fonterelli SPAC2 AG, is a pioneering company based in Pinneberg, Germany. Since its incorporation in 2021, the company has focused on the development and distribution of innovative products across diagnostics, therapeutics, and cold plasma technology. With a mission to revolutionize medical solutions and healthcare, Viromed Medical AG is positioned at the cutting edge of medical technology, committed to improving patient outcomes through its advanced product offerings and research initiatives.
Viromed Medical AG offers a range of diagnostic tools and kits designed for the detection and monitoring of various diseases. These products leverage the latest advancements in biotechnology to provide accurate, timely, and cost-effective diagnostic solutions for healthcare providers and patients alike.
The company develops and distributes a variety of therapeutic products aimed at treating and managing a wide spectrum of conditions. By focusing on innovation and efficacy, Viromed Medical AG delivers novel therapeutic options that contribute to better health outcomes and improve the quality of life for patients undergoing treatment.
One of Viromed Medical AG's most groundbreaking service areas is the application of cold plasma technology in medicine. This cutting-edge technology offers a non-invasive, highly effective approach to sterilization, wound healing, and possibly even cancer treatment. Cold plasma technology represents a significant step forward in medical science, showcasing Viromed Medical AG's commitment to leading the way in healthcare innovation.